Solara Active Pharma Sciences · tone and specificity signals across the available quarters.
Language signals
We sell our gross margin at 21% in spite of us selling the product at at least 15 to 17% greater than our competition because we sell to Big Pharma and they are completely aware of the situation and are aligned with our current pricing.
The ibuprofen derivatives is a very significant business for us and it is a growing business. It's part of the growth business. What we talk about ibuprofen is the ibuprofen plain raw material.
The fundamentals of our business remain strong. I do firmly believe that we have a resilient operating model, a very robust compliance framework and a diversified portfolio across key markets.
Our business has delivered the highest revenue, gross margins and EBITDA in the previous eight quarters.
We have an internal target of making Solara debt free by FY29.
We are not backward integrated by any means. We source the IBA from third party.